180 related articles for article (PubMed ID: 31428099)
1. Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M; Bueno D; González-Navarro P; Brito A; Fernández L; Escudero A; Valentín J; Mestre-Durán C; Arranz-Álvarez M; Pérez de Diego R; Mendiola M; Pozo-Kreilinger JJ; Pérez-Martínez A
Front Immunol; 2019; 10():1814. PubMed ID: 31428099
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
4. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4.
Kashima K; Watanabe M; Sato Y; Hata J; Ishii N; Aoki Y
Cancer Sci; 2014 Oct; 105(10):1343-50. PubMed ID: 25154453
[TBL] [Abstract][Full Text] [Related]
8. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Kuçi S; Rettinger E; Voss B; Weber G; Stais M; Kreyenberg H; Willasch A; Kuçi Z; Koscielniak E; Klöss S; von Laer D; Klingebiel T; Bader P
Haematologica; 2010 Sep; 95(9):1579-86. PubMed ID: 20378565
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.
Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'Aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G
Cancer Res; 2014 Jan; 74(1):119-29. PubMed ID: 24356422
[TBL] [Abstract][Full Text] [Related]
10. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
11. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A; Valeri A; Córdoba L; García-Ortiz A; Ortiz A; Sánchez-Vega L; Graña-Castro O; Fernández L; Carreño-Tarragona G; Pérez M; Megías D; Paciello ML; Sánchez-Pina J; Pérez-Martínez A; Lee DA; Powell DJ; Río P; Martínez-López J
Blood Cancer J; 2021 Aug; 11(8):146. PubMed ID: 34392311
[TBL] [Abstract][Full Text] [Related]
12. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
[TBL] [Abstract][Full Text] [Related]
13. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
14. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
15. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
[TBL] [Abstract][Full Text] [Related]
16. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
18. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
19. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]